Home
About us
Technology
News
Publications
Careers
Contact


Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.

Axerion was established in New Haven to develop and commercialize intellectual property licensed from Yale University based on work done in Dr. Stephen Strittmatter’s laboratory. Axerion’s proprietary technology platforms include blockers of β-amyloid (Aβ) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.